Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Allogeneic Stem Cell Transplantation in Treatment of Aggressive Lymphomas: Case Series (CROSBI ID 98299)

Prilog u časopisu | stručni rad

Labar, Boris ; Bogdanić, Vinko ; Nemet, Damir ; Mrsić, Mirando ; Serventi-Seiwerth, Ranka ; Sertić, Dubravka ; Golubić-Čepulić, Branka ; Vrtar, Mladen ; Šantek, Fedor ; Batinić, Drago et al. Allogeneic Stem Cell Transplantation in Treatment of Aggressive Lymphomas: Case Series // Croatian medical journal, 43 (2002), 5; 565-568-x

Podaci o odgovornosti

Labar, Boris ; Bogdanić, Vinko ; Nemet, Damir ; Mrsić, Mirando ; Serventi-Seiwerth, Ranka ; Sertić, Dubravka ; Golubić-Čepulić, Branka ; Vrtar, Mladen ; Šantek, Fedor ; Batinić, Drago ; Mikulić, Mirta ; Pulanić, Dražen

engleski

Allogeneic Stem Cell Transplantation in Treatment of Aggressive Lymphomas: Case Series

Aim. To assess the outcome of allogeneic stem cell transplantation in patients with aggressive lymphoma. Methods. Between 1991 and 2002, 22 patients with aggressive lymphoma in advanced phase of the disease under-went allogeneic stem cell transplantation at the Division of Haematology, Zagreb University Hospital Center. Seventeen patients received stem cells from the bone marrow. Eighteen patients underwent total body irradiation and received cyclophosphamide for conditioning, whereas the rest of the patients received busulfan and cyclophosphamide (n=2) or chemotherapeutic protocol combining carmustine, melphalan, etoposide, and cytarabine (BEAM regimen)(n=2). All patients received cyclosporin and short methotrexate for the prophylaxis of graft-versus-host disease (GVHD).Results. Three months after allo-transplantation, 17 patients had complete remission, 3 patients had active disease, and the outcome in 2 patients was early death. Nine patients were alive and in complete remission for 4 to 124 months, whereas 13 patients died (8 because of disease progression and 3 because of GVHD and infection). The probability of overall survival at 4 years was 47%. Conclusion. Allogeneic transplantation is an effective therapy for advanced aggressive lymphoma. Because of high treatment-related toxicity and mortality, prospective trials are needed to asses the best time when to apply this treat-ment.

antineoplastic combined chemotherapy protocols; busulfan; carmustine; cyclophosphamide; cytarabine; etoposi-de;

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

43 (5)

2002.

565-568-x

objavljeno

0353-9504

Povezanost rada

Javno zdravstvo i zdravstvena zaštita

Poveznice
Indeksiranost